Grünenthal GmbH
About Grünenthal GmbH
Certifications
Categories

-
DE
-
2015On CPHI since
-
4Certificates
-
1000 - 4999Employees
Company types
Products from Grünenthal GmbH (14)
-
Product Biopharma Assembly and Packaging
Biopharma Assembly and Packaging Services
When contracting medicine supply for patients, it is essential to have a partner that delivers excellence. Read more about Grünenthal PRO: https://www.grunenthal-pro.com -
Product Unit Dose Nasal Spray
Unit Dose Nasal Spray -
Product Integrated Manufacturing Services
Integrated Manufacturing Services -
Product Sterile Ampoule Filling/Packaging
Sterile Ampoule Filling/Packaging -
Product Wallet Packaging
We are also highly experienced in the handing of controlled substances.
-
Product Pregabalin FDF
Pregabalin 75 and 150 mg tablets -
Product Tramadol HCl
Grünenthal GmbH offers a selected range of products which includes Tramadol HCl, as API, bulk and/ or finished dosage form. Please contact us for more information.
-
Product Betahistine diHCl
Grünenthal GmbH offers a selected range of products which includes Betahistine diHCl, as API, bulk tablets and/ or finished dosage form. Please contact us for more information.
-
Product Betahistine 12.5 mg/ml Oral Drops
Glass bottle containing 100 ml oral solution with disposal pump. -
Product Calcium carbonate + vit D3
Calcium carbonate + vit D3 tablets -
Product Calcium carbonate 320 mg & 450mg
Calcium carbonate 320 mg& 450mg tablets -
Product Morphine solution 2%
Morphine solution 2% x 60ml
Grünenthal GmbH Resources (3)
-
News Grünenthal Report 2022-2023
2022 was yet another fantastic year for Grünenthal. The company exceeded its financial and non-financial targets. Our revenue reached €1.7 billion, an increase of 13 percent compared to 2021. The adjusted EBIDTA reached €438 million, an increase of 18 percent over 2021, and has more than tripled since 2017. These record results were driven by increased demand for pain treatments and excellent sales performance across regions. Its financial success positions Grünenthal well to further invest in advancing the R&D pipeline, continuing the M&A strategy and growing the business in the United States. -
News Strong new ESG rating puts Grünenthal in top 2% of the pharmaceuticals subindustry
The latest independent rating confirms Grünenthal’s improved approach to managing Environmental, Social and Governance (ESG) topics – and evaluates the company as the leader in its peer group, with a low ESG risk rating. -
News EcoVadis Silver Medal!
We are celebrating an EcoVadis silver medal!
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance